From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies

被引：92

作者：

Lu, Hui ^{[1
]}

Zhao, Xiaoyan ^{[1
]}

Li, Ziying ^{[1
]}

Hu, Yu ^{[1
]}

Wang, Huafang ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Union Hosp, Dept Hematol, Tongji Med Coll, Wuhan, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2021年 / 11卷

基金：

中国国家自然科学基金;

关键词：

chimeric antigen receptor; natural killer cells; T cells; immunotherapy; hematological malignancies; NATURAL-KILLER-CELLS; CHIMERIC-ANTIGEN-RECEPTOR; CLINICAL-TRIAL; NK-92; CELLS; CELLULAR IMMUNOTHERAPY; MYELOID MALIGNANCIES; VIVO EXPANSION; MESSENGER-RNA; STEM-CELLS; PHASE-II;

D O I：

10.3389/fonc.2021.720501

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The approval of CD19 chimeric antigen receptor (CAR)-engineered T (CAR-T) cell products in B-cell malignancies represents a breakthrough in CAR-T cell immunotherapy. However, the remaining limitations concerning the graft-versus-host disease (GVHD) and other adverse effects (e.g., cytokine release syndromes [CRS] and neurotoxicity) still restrict their wider applications. Natural killer (NK) cells have been identified as promising candidates for CAR-based cellular immunotherapy because of their unique characteristics. No HLA-matching restriction and abundant sources make CAR-engineered NK (CAR-NK) cells potentially available to be off-the-shelf products that could be readily available for immediate clinical use. Therefore, researchers have gradually shifted their focus from CAR-T cells to CAR-NK cells in hematological malignancies. This review discusses the current status and applications of CAR-NK cells in hematological malignancies, as well as the unique advantages of CAR-NK cells compared with CAR-T cells. It also discusses challenges and prospects regarding clinical applications of CAR-NK cells.

引用

页数：13

共 128 条

[31] Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer [J].

Daher, May ;

Rezvani, Katayoun .

CANCER DISCOVERY, 2021, 11 (01) :45-58

[32] Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells [J].

Daher, May ;

Basar, Rafet ;

Gokdemir, Elif ;

Baran, Natalia ;

Uprety, Nadima ;

Cortes, Ana Karen Nunez ;

Mendt, Mayela ;

Kerbauy, Lucila Nassif ;

Banerjee, Pinaki P. ;

Shanley, Mayra ;

Imahashi, Nobuhiko ;

Li, Li ;

Lim, Francesca Lorraine Wei Inng ;

Fathi, Mohsen ;

Rezvan, Ali ;

Mohanty, Vakul ;

Shen, Yifei ;

Shaim, Hila ;

Lu, Junjun ;

Ozcan, Gonca ;

Ensley, Emily ;

Kaplan, Mecit ;

Nandivada, Vandana ;

Bdiwi, Mustafa ;

Acharya, Sunil ;

Xi, Yuanxin ;

Wan, Xinhai ;

Mak, Duncan ;

Liu, Enli ;

Xin Ru Jiang ;

Ang, Sonny ;

Muniz-Feliciano, Luis ;

Li, Ye ;

Wang, Jing ;

Kordasti, Shahram ;

Petrov, Nedyalko ;

Varadarajan, Navin ;

Marin, David ;

Brunetti, Lorenzo ;

Skinner, Richard J. ;

Lyu, Shangrong ;

Silva, Leiser ;

Turk, Rolf ;

Schubert, Mollie S. ;

Rettig, Garrett R. ;

McNeill, Matthew S. ;

Kurgan, Gavin ;

Behlke, Mark A. ;

Li, Heng ;

Fowlkes, Natalie W. .

BLOOD, 2021, 137 (05) :624-636

[33] Revisiting human natural killer cell subset function revealed cytolytic CD56dimCD16+ NK cells as rapid producers of abundant IFN-γ on activation [J].

De Maria, Andrea ;

Bozzano, Federica ;

Cantoni, Claudia ;

Moretta, Lorenzo .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (02) :728-732

[34] 'Off-the-shelf' allogeneic CAR T cells: development and challenges [J].

Depil, S. ;

Duchateau, P. ;

Grupp, S. A. ;

Mufti, G. ;

Poirot, L. .

NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (03) :185-199

[35] Cryopreservation has no effect on function of natural killer cells differentiated in vitro from umbilical cord blood CD3+ cells [J].

Domogala, Anna ;

Madrigal, J. Alejandro ;

Saudemont, Aurore .

CYTOTHERAPY, 2016, 18 (06) :754-759

[36] The Interplay between MicroRNAs and the Components of the Tumor Microenvironment in B-Cell Malignancies [J].

El-Daly, Sherien M. ;

Bayraktar, Recep ;

Anfossi, Simone ;

Calin, George A. .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)

[37] Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12 [J].

Floros, Theofanis ;

Tarhini, Ahmad A. .

SEMINARS IN ONCOLOGY, 2015, 42 (04) :539-548

[38] New targets and technologies for CAR-T cells [J].

Freitag, Fabian ;

Maucher, Marius ;

Riester, Zeno ;

Hudecek, Michael .

CURRENT OPINION IN ONCOLOGY, 2020, 32 (05) :510-517

[39] The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor [J].

Gasser, S ;

Orsulic, S ;

Brown, EJ ;

Raulet, DH .

NATURE, 2005, 436 (7054) :1186-1190

[40] Natural Killer cells and monoclonal antibodies: Two partners for successful antibody dependent cytotoxicity against tumor cells [J].

Gauthier, Melanie ;

Laroye, Caroline ;

Bensoussan, Daniele ;

Boura, Cedric ;

Decot, Veronique .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 160

← 1 2 3 4 5 6 7 8 9 10 →